EKF has issued a positive H1 trading update, continuing the recent pattern of raising and beating expectations. Revenues were in line but EBITDA ahead on good cost control. Cash generation was again strong and the outlook for H2 is described as encouraging. Including the RenalytixAI stake (which is up 172% since IPO last year), cash and marketable securities exceeded £20m, prompting the intention to declare a maiden dividend this year. We prudently make no changes to our estimates at this stage ....
15 Jul 2019
Positive H1 trading, intention to pay FY dividend
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive H1 trading, intention to pay FY dividend
EKF Diagnostics Holdings plc (EKF:LON) | 28.0 0 0.6% | Mkt Cap: 126.8m
- Published:
15 Jul 2019 -
Author:
Chris Glasper -
Pages:
3
EKF has issued a positive H1 trading update, continuing the recent pattern of raising and beating expectations. Revenues were in line but EBITDA ahead on good cost control. Cash generation was again strong and the outlook for H2 is described as encouraging. Including the RenalytixAI stake (which is up 172% since IPO last year), cash and marketable securities exceeded £20m, prompting the intention to declare a maiden dividend this year. We prudently make no changes to our estimates at this stage ....